Daniel Cepin, MD
Interventional Cardiology · Chula Vista, CANPI 1053320556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,937 and has fallen 76.6% since, to $453 in 2024. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.
Across 293 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$823
- Novartis$801
- Johnson & Johnson$740
- Medtronic$693
- Biotronik Inc.$673
- Boston Scientific$538
- plus $4K from 27 others
What the payments were for
- Food & beverage$8,04197%
- Education$2323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $823 |
| Novartis | 50 | $801 |
| Johnson & Johnson | 29 | $740 |
| Medtronic(2 entities) | 17 | $693 |
| Biotronik Inc. | 30 | $673 |
| Boston Scientific | 15 | $538 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 28 | $533 |
| AstraZeneca | 18 | $422 |
| Merck | 15 | $342 |
| Philips North America LLC | 1 | $336 |
| Pfizer | 18 | $273 |
| Amgen | 7 | $243 |
| Boehringer Ingelheim | 9 | $218 |
| Braemar Manufacturing, LLC | 1 | $216 |
| Shockwave Medical, Inc | 1 | $178 |
| E.r. Squibb & Sons, L.L.C. | 8 | $170 |
| Kiniksa Pharmaceuticals, Ltd. | 8 | $169 |
| Alnylam Pharmaceuticals Inc. | 5 | $165 |
| Edwards Lifesciences | 1 | $138 |
| Bayer | 2 | $135 |
| Cvrx, Inc. | 1 | $98 |
| Sanofi-aventis U.S. LLC | 4 | $81 |
| Chiesi USA, Inc. | 3 | $49 |
| Kestra Medical Technology Services, Inc. | 1 | $39 |
| Abiomed | 1 | $32 |
| Atricure, Inc. | 1 | $25 |
| Recor Medical Inc | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $23 |
| AbbVie | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Bardy Diagnostics, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,273 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $138,426 |
| EntrestoSacubitril/Valsartan | 61 | $77,653 |
| XareltoRivaroxaban | 53 | $55,271 |
| MultaqDronedarone Hcl | 12 | $24,158 |
| BrilintaTicagrelor | 18 | $21,213 |
| Repatha SureclickEvolocumab | 14 | $19,098 |
| Losartan Potassium | 292 | $3,924 |
| Nifedipine ErNifedipine | 146 | $3,659 |
| Amlodipine Besylate | 173 | $1,646 |
| Atorvastatin Calcium | 86 | $1,500 |
| Valsartan | 34 | $1,363 |
| Metoprolol Succinate | 68 | $1,308 |
| Hydralazine Hcl | 77 | $947 |
| Metoprolol Tartrate | 108 | $869 |
| Rosuvastatin Calcium | 38 | $868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $273 | $138,426120 claims |
| NovartisEntresto | $801 | $77,65361 claims |
| Johnson & JohnsonXarelto | $740 | $55,27153 claims |
| Sanofi-aventis U.S. LLCMultaq | $81 | $24,15812 claims |
| AstraZenecaBrilinta | $422 | $21,21318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Chula Vista
- Mehran MoussavianChula Vista$149K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.